Stock Analysis
Solventum CorporationSOLV
P/E 10.19×· 3Y range 7.22–51.05×· 33th percentile of history
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsBuy22 analystsP/E 10.2× sits at the 33rd percentile of its 2.54072553045859-year history.
Cash covers 17% of debt · FY 2025.
PMP Verdict
Weak fundamentals
Risks
- Growth12
- Quality47
Weak fundamentals — valuation is the only support.
Market context
-2.3% today· Z 2.5σ· SOLV fell 2.32% on below-average volume ahead of its upcoming Q3 earnings release.
Bull Case
- ✓ROE 28.4% — efficient capital deployment
Why is SOLV moving?
TechnicalSOLV fell 2.32% on below-average volume ahead of its upcoming Q3 earnings release.
Profile
growth and earnings quality lag behind.
How is each axis scored?
- Valuation50/100 · Moderate
- P/E vs own history (33th pct)20/25
- FCF yield (-0.8%)0/25
- P/S (1.8x)25/25
- EV/EBIT (32.8x)5/25
- Growth12/100 · Weak
- Revenue CAGR (0.5%)6/25
- Net income CAGR (1.6%)6/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (-15.0%)0/25
- Profitability55/100 · Moderate
- ROIC (4.9%)5/25
- ROE (28.4%)25/25
- Net margin (17.3%)20/25
- Operating margin (6.9%)5/25
- Financial Health52/100 · Moderate
- Altman Z (1.95)10/25
- Current ratio (1.23)12/25
- Interest coverage (6.1x)18/25
- Net cash / debt (D/A 29%)12/25
- Quality47/100 · Weak
- Piotroski F (6/9)15/25
- Beneish M (-1.80)12/25
- FCF conversion (-8%)0/25
- Margin stability (σ 7.0%)20/25
- Moat61/100 · Moderate
- ROIC >12% years (1/5 yrs)0/25
- Median gross margin (57.3%)25/25
- FCF-positive years (4/5 yrs)18/25
- Worst-year net margin (worst 5.8%)18/25
Risk Flags
- ⚠Negative FCF margin (-0.0%) — burning cash
About Solventum Corporation
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. Show more
At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
Headquarters: EAGAN, MN · Employees: 20,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
50CP/E (TTM)10.2xA
Grade A: CheapPrice / TTM EPS (own statements) — vs own 3Y history: 7.2x–51.1x · 33rd pct
P/FCF85.0xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative · CapEx exceeds operating cash flow (156% of OCF) — reported FCF understates normalized earning power in this investment phase
FCF Yield-0.8%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 3Y history: -1.9%–7.7% · 14th pct · CapEx exceeds operating cash flow (156% of OCF) — reported FCF understates normalized earning power in this investment phase
P/S (TTM)1.76xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own 3Y history: 1.3x–6.0x · 60th pct
EV/EBIT32.8xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 3Y history: 6.9x–50.9x · 90th pct
EV/Sales2.4xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E12.0xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.89xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.04A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
CapEx exceeds OCF: CapEx exceeds operating cash flow (156% of OCF) — reported FCF understates normalized earning power in this investment phase
Profitability
55CROIC4.9%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE28.4%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA10.1%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin17.3%A
Grade A: HighNet Income / Revenue
Operating Margin6.9%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin54.7%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-1.4%D
Grade D: LowFCF / Revenue · CapEx exceeds operating cash flow (156% of OCF) — reported FCF understates normalized earning power in this investment phase
True FCF Margin-3.4%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost · CapEx exceeds operating cash flow (156% of OCF) — reported FCF understates normalized earning power in this investment phase
Growth
12ERevenue CAGR0.5%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR1.6%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth-15.0%D
Grade D: Decl.Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income11.6%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue2.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
52CAltman Z-Score1.95C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.23xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.70xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage6.1xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF · CapEx exceeds operating cash flow (156% of OCF) — reported FCF understates normalized earning power in this investment phase
Net Debt/EBIT7.3xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity1.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.17xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
47D+Piotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-1.80C
Grade C: Gray zoneEarnings manipulation risk. < -2.22 Safe
FCF Conversion-8.2%D
Grade D: PoorFCF / Net Income · CapEx exceeds operating cash flow (156% of OCF) — reported FCF understates normalized earning power in this investment phase
Margin Stability7.0%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue3.9%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.59xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Hanson Bryan C Filed | Hanson Bryan C | Option exercise | -67261 | |
Hanson Bryan C Filed | Hanson Bryan C | Tax withholding | -26468 | |
Hanson Bryan C Filed | Hanson Bryan C | Option exercise | +67.3K | |
Zieselman Neil Craig Filed | Zieselman Neil Craig | Grant / award | +6.9K | |
Edwards Shirley Ann Filed | Edwards Shirley Ann | Grant / award | +3.3K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Mily Elizabeth Filed | Mily Elizabeth | Grant / award | +3.3K | |
Wilson Darryl L. Filed | Wilson Darryl L. | Grant / award | +3.3K | |
DeVore Susan D. Filed | DeVore Susan D. | Grant / award | +3.3K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
61BROIC >12% Years1/5 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)57.3%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years4/5 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor5.8%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$8.42
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$2.37
Cash & short-term investments per share (Finnhub)
Book Value / Share$28.22
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$5.04B
Total debt obligations (short + long term)
Cash & Equiv.$878.00M
Cash and short-term investments
Net Debt$4.16B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$5.05B
Shareholders' equity (book value)
Asset / Liability1.55xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$14.61B
Current Market Capitalization
Beta0.74B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Solventum Corporation (SOLV)
SOLV is down 2.33% at the last close — SOLV fell 2.32% on below-average volume ahead of its upcoming Q3 earnings release.. Piotroski F-Score of 6/9 indicates mixed fundamentals for Solventum Corporation. Altman Z-Score of 1.95 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out.
- Free-cash-flow margin is negative (-1%) — the business currently burns cash.
- Company has negative FCF, making debt repayment from operations difficult.
- Return on equity of 28.4% is well above the market average.
See how SOLV ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all SOLV moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 16 | Regular | 85.72 | -2.44% | -2.63 |
| Oct 16 | After-hours | 85.81 | -2.33% | -2.52 |
| Oct 12 | After-hours | 85.41 | -2.15% | -2.39 |
Frequently Asked Questions about SOLV
What is the current Solventum Corporation (SOLV) stock price?
SOLV is trading at $85.81 at the last market close, down 2.33% on the session. PreMarketPrice tracks SOLV pre-market, intraday and after-hours prices.
Is SOLV stock a buy right now?
PreMarketPrice's quantitative model rates Solventum Corporation's financial health at 52/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is SOLV stock overvalued?
Solventum Corporation trades at a trailing P/E of 10.2 and our valuation score rates it 50/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Solventum Corporation report earnings?
No confirmed earnings date is currently scheduled for SOLV. The Earnings section lists recent reports and updates as dates are announced.
What sector does Solventum Corporation operate in?
Solventum Corporation operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does Solventum Corporation do?
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum.
About Solventum Corporation (SOLV) Stock
Solventum Corporation (SOLV) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, Solventum Corporation is trading at $85.81, down 2.33% on the day with a market capitalization of $14.6 billion. The financial health score for SOLV is 52/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for SOLV stock.
SOLV Stock Analysis & Key Metrics
On PreMarketPrice, you can track Solventum Corporation (SOLV) across multiple dimensions:
- Pre-market price & movement: Real-time SOLV stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for SOLV with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Solventum Corporation across multiple reporting periods.
- Financial health score: A composite score of 52/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for SOLV.
- Sector peers: Compare SOLV against 6 other healthcare stocks on key financial metrics.
Is SOLV a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Solventum Corporation (SOLV) as an investment. The financial health score of 52/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Solventum Corporation (SOLV) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.